Brokerages expect Aevi Genomic Medicine Inc (NASDAQ:GNMX) to announce earnings per share (EPS) of ($0.16) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Aevi Genomic Medicine’s earnings, with the lowest EPS estimate coming in at ($0.17) and the highest estimate coming in at ($0.15). Aevi Genomic Medicine reported earnings per share of ($0.23) in the same quarter last year, which suggests a positive year over year growth rate of 30.4%. The business is expected to announce its next earnings report on Thursday, November 1st.

On average, analysts expect that Aevi Genomic Medicine will report full-year earnings of ($0.59) per share for the current fiscal year, with EPS estimates ranging from ($0.61) to ($0.57). For the next fiscal year, analysts expect that the firm will post earnings of ($0.92) per share, with EPS estimates ranging from ($1.27) to ($0.56). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover Aevi Genomic Medicine.

Aevi Genomic Medicine (NASDAQ:GNMX) last announced its earnings results on Thursday, August 2nd. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.01.

Separately, ValuEngine upgraded shares of Aevi Genomic Medicine from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd.

In other news, Director Sol J. Barer bought 2,551,020 shares of the company’s stock in a transaction that occurred on Wednesday, August 15th. The shares were purchased at an average price of $0.96 per share, for a total transaction of $2,448,979.20. Following the acquisition, the director now directly owns 1,028,032 shares of the company’s stock, valued at approximately $986,910.72. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 11.70% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Renaissance Technologies LLC boosted its position in shares of Aevi Genomic Medicine by 515.8% during the 4th quarter. Renaissance Technologies LLC now owns 93,600 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 78,400 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Aevi Genomic Medicine by 4,715.1% during the 1st quarter. JPMorgan Chase & Co. now owns 101,118 shares of the biotechnology company’s stock valued at $203,000 after acquiring an additional 99,018 shares in the last quarter. Finally, Wedbush Securities Inc. acquired a new stake in shares of Aevi Genomic Medicine during the 2nd quarter valued at about $233,000. Institutional investors own 21.56% of the company’s stock.

GNMX traded down $0.03 during trading on Monday, hitting $1.26. The stock had a trading volume of 71,423 shares, compared to its average volume of 142,853. The company has a market capitalization of $75.36 million, a PE ratio of -1.52 and a beta of 0.99. Aevi Genomic Medicine has a 12 month low of $0.83 and a 12 month high of $2.65.

About Aevi Genomic Medicine

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.

Featured Story: Discover Your Risk Tolerance

Get a free copy of the Zacks research report on Aevi Genomic Medicine (GNMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aevi Genomic Medicine (NASDAQ:GNMX)

Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.